ALAnna Lundahl

Anna Lundahl

*This is an algorithmically generated author record based on publicly available information.

Anna Lundahl has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Anne-Kristina Mercier

    Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden

    1 shared publication
  • Atul Gupta

    Department of Paediatric Respiratory Medicine, King's College Hospital, London, United Kingdom

    1 shared publication
  • Beata Pawlikowska

    Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland

    1 shared publication
  • Cecil Chen

    Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, South San Francisco, CA, United States

    1 shared publication
  • Dave Singh

    Manchester University NHS Foundation Trust, University of Manchester, Manchester, United Kingdom

    1 shared publication
  • David Close

    Research and Early Development, Respiratory and Immunology AstraZeneca Cambridge UK

    1 shared publication

Latest Publications

  • Open Access

    AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma

    by Anna Lundahl, Rod Hughes, Joachim Almquist, David Close, Jukka Mäenpää, Ulrika Tehler, Tina Jellesmark Jensen, Szilárd Nemes, Anne‐Kristina Mercier, Zala Jevnikar, et al.

    Aims: Inhaled corticosteroids (ICS) plus bronchodilator are recommended for the treatment of asthma. Targeting the JAK1‐dependent pathway may be an alternative for asthma management in patients with incomplete response to ICS. The aim of this study was to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD0449, a novel JAK1 selective inhibitor, following inhaled (dry powder, nebulized) and intravenous administration to healthy participants and patients with mild asthma. Methods: This was a randomized, single‐blind, placebo‐controlled Phase 1 study (NCT03766399) of single‐ and multiple‐ascending doses conducted using a three‐part design. Healthy participants and patients with mild asthma aged 18–55 years were recruited. The study evaluated safety, tolerability, PK and PD of AZD0449. PD was measured as the effect on fractional exhaled nitric oxide (FeNO). Systemic target engagement was measured using phosphorylation of signal transducer and activator of transcription 6 (pSTAT6). Results: A total of 125 participants were included in the study. No drug‐related safety concerns emerged. Following inhaled administration, AZD0449 showed low, dose‐proportional, systemic exposures and elimination from plasma was partly absorption‐limited, suggesting lung retention and supporting once‐daily dosing. At the dose levels evaluated (1.2–5.0 mg), there was no significant anti‐inflammatory effect (reduction in FeNO) with AZD0449 vs . placebo, following repeated dosing for 14 days. Furthermore, there was no significant suppression of pSTAT6. Conclusions: AZD0449 was safely administered via inhalation, with low systemic exposure and lung retention. This study provides a greater understanding of inhaled dosing of small molecule JAK1 inhibitors for the treatment of asthma. No effect on PD biomarkers (FeNO and STAT6) was observed.


  • Pharmacokinetics, pharmacodynamics and safety of tezepelumab in children with asthma

    by Anna Lundahl, Jonathan Grigg, Gillian Hunter, Beata Pawlikowska, Cecil Chen, Jacob Leander, Michael Levin, Atul Gupta, James Paton, Katharine C Pike, et al.

    Background: Tezepelumab is approved for the treatment of patients aged ≥12 years with severe asthma. Objective: TRAILHEAD (NCT04673630) evaluated the pharmacokinetics (PK), pharmacodynamics (PD) and safety of tezepelumab in children with asthma. Methods: TRAILHEAD was a phase 1, multicentre, open-label study in children (5–11 years) with mild, moderate or severe asthma requiring daily controller medication use. PK (primary outcome), PD (exploratory outcome) and safety were evaluated for up to 85 days after a single subcutaneous dose of tezepelumab 70 mg. Results: Of 23 children enrolled, 18 received treatment and completed the study (median age, 8 years; 61% male). Max geometric mean serum concentration of tezepelumab (24.6 μg/mL) was observed at a median time of 3.5 days post dose, followed by exponential decline with a mean terminal half-life of 25.7 days (Figure). Mean area under the concentration–time curve was 974 μg*day/mL. Changes in biomarkers from baseline (blood eosinophil count, serum total IgE and FeNO) reflected the expected PD effects of tezepelumab. Seven patients (39%) reported adverse events; all were mild or moderate intensity and considered by the investigator to be unrelated to treatment. Conclusion: The PK, PD and safety after a single 70 mg dose of tezepelumab in children were as expected from previous studies in other age groups, supporting further development of tezepelumab for children with asthma. erj;64/suppl_68/PA3562/F1 F1 F1


  • Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions

    by Luna Prieto Garcia, David Janzén, Kajsa P. Kanebratt, Hans Ericsson, Hans Lennernäs, Anna Lundahl

    Physiologically based pharmacokinetic (PBPK) modeling for itraconazole using a ′bottom-up′ approach is challenging. Not only due to complex saturable pharmacokinetics (PK) and presence of three metabolites exhibiting CYP3A4 inhibition, but also because discrepancies in reported in vitro data. The overall objective of this study is to provide a comprehensive mechanistic PBPK model for itraconazole to increase the confidence in its drug-drug interaction (DDI) predictions. To achieve this, key in vitro and in vivo data for itraconazole and its major metabolites were generated. This data was crucial to develop a novel ′bottom-up′ PBPK model in Simcyp® for itraconazole and two of its major metabolites: hydroxy- itraconazole (OH-ITZ) and keto-itraconazole (keto-ITZ). Performance of the model was validated using pre-specified acceptance criteria against different dosing regimens, formulations for 29 PK and DDI studies with midazolam and other CYP3A4 substrates. The main outcome is an accurate PBPK model that simultaneously predicts the PK profiles of itraconazole, OH-ITZ and keto-ITZ. In addition, DDI between midazolam and itraconazole were successfully predicted within a 2-fold error for all the studies. Prediction precision and bias of DDI expressed as geometric mean fold error were for the area under the concentration- time curve and peak concentration, 1.06 and 0.96, respectively. To conclude, in this paper a comprehensive dataset for itraconazole and its metabolites is provided that enables bottom-up mechanism based PBPK modeling. The presented model is applicable for studying the contribution from the metabolites and allows improved assessments of itraconazole DDI.